Tweet
I have download the source code of the ALLPATHS from the MIT. But I can not find any information about how to compile or install. Where can I get the information about how to install and use?
-
-
The manual seems to be a separate download to the .tgz package:
ftp://ftp.broad.mit.edu/pub/crd/ALLP....0.manual.docx -
/usr/lib/gcc/x86_64-redhat-linux/4.3.2/../../../../include/c++/4.3.2/backward/auto_ptr.h:196
./kmer_freq/EvaluateStrongKmers.cc:302:
when I compile the software, it report a bug. The above files seem to be something wrong.Comment
-
I think I solve the problem after I change the system language from Chinese to English.Comment
-
Hi anyone1985Originally posted by anyone1985 View Post
Are you running AllPaths? Does it work? What version are you using? I tried with version 3.3.2 and i always get error that says -
Looks like the command PrepareAllPathsInput did not complete
Did you get this error?
What command do you give for TARGET=import and TARGET=Standard
thanks in advance
himalayaComment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment